Tweet
I would like to get in touch with someone who have used QIAseq targeted DNA panel. We are struggling with cfDNA libraries and I am wondering if anyone are experiencing the same?
-
-
I do not have experience with QIAseq targeted DNA panel. But can I ask what struggles do you have with cfDNA libraries?
How big is the panel that you are trying to profile?
Thanks!
Cheers,
Sergio -
Hi everyone,
our genetic testing software 'Seamless NGS' offers an easy-to-use workflow for the analysis of Qiagen's QiaSeq panels.
Before mapping the reads, the common sequence and the UMIs are clipped away. After mapping, the UMIs sequences are properly used to correct for PCR clones and the single amplicon primer is clipped away to ensure correct and unbiased variant calling. The workflow was developed, tested and validated together with a trustworthy pathological laboratory at one of the oldest university hospitals in Germany. Having long-lasting experience in that field, together with them, ecSeq was able to get the most out of the QiaSeq panel.
If you are interested in our solution, please check www.seamless-ngs.com and/or write us a short email ([email protected]) to make an appointment for a personal live demo (online).
Last edited by ecSeq Bioinformatics; 05-13-2019, 01:15 AM.ecSeq Bioinformatics is Europe’s leading provider of hands-on bioinformatics workshops and professional data analysis in the field of Next-Generation Sequencing (NGS).Comment
-
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM -
Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.07-01-2026, 11:43 AM
Comment